Xilio Therapeutics (XLO) Operating Income Growth (1y) (2021 - 2026)
Xilio Therapeutics (XLO) Operating Income Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,538.84 Bn | 65,538.56 Bn | - | -24.89% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 469.46 Bn | 464.67 Bn | 1.35 Bn | 2,150.96% |
| 5 | Vertex Pharmaceuticals | 122.69 Bn | 115.45 Bn | 2.59 Bn | 80.62% |
| 6 | Regeneron Pharmaceuticals | 70.41 Bn | 61.65 Bn | 3.31 Bn | 8.65% |
| 7 | Belite Bio | 62.84 Bn | 62.84 Bn | - | - |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn | 145.20% |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn | 1,386.07% |
| 10 | Xilio Therapeutics | 145.98 Mn | -4.32 Mn | - | -1.88% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.88% |
| Dec 31, 2025 | 13.16% |
| Sep 30, 2025 | 86.93% |
| Jun 30, 2025 | 2.30% |
| Mar 31, 2025 | 20.79% |
| Dec 31, 2024 | 24.83% |
| Sep 30, 2024 | 14.97% |
| Jun 30, 2024 | 26.90% |
| Mar 31, 2024 | 25.67% |
| Dec 31, 2023 | 21.74% |
| Sep 30, 2023 | 14.08% |
| Jun 30, 2023 | 18.07% |
| Mar 31, 2023 | -10.85% |
| Dec 31, 2022 | -18.46% |
| Sep 30, 2022 | -26.60% |
| Jun 30, 2022 | -6.72% |
| Mar 31, 2022 | -28.47% |
| Dec 31, 2021 | 5.04% |
| Sep 30, 2021 | -9.15% |